Vanguard Capital Management
ORKA

Vanguard Capital Management’s Oruka Therapeutics ORKA Stock Holding History

Vanguard Capital Management’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$225M Buy
2,360,971
+501,340
+27% +$33.4M ﹤0.01% 1061
2026
Q1 		$91.2M Buy
+1,859,631
New +$64.6M ﹤0.01% 1519

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Vanguard Capital Management's ORKA Position: Q2 2026 in Review

Vanguard Capital Management increased its Oruka Therapeutics (ORKA) stake by 27% in Q2 2026, buying an estimated $33.4M and bringing the position to 2,360,971 shares worth $225M. The position accounts for ﹤0.01% of the portfolio, ranked #1061.

Vanguard Capital Management first reported a position in ORKA in Q1 2026 and has held it in 2 quarters since. 255 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

  • Vanguard Capital Management held 2,360,971 shares of Oruka Therapeutics worth $225M as of Q2 2026.
  • Vanguard Capital Management bought 501,340 Oruka Therapeutics shares in Q2 2026, an estimated $33.4M.
  • Oruka Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #1061 holding.
  • Vanguard Capital Management first reported a position in Oruka Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 255 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.